Adis Journal Podcasts

Listen to podcasts with key opinion leaders in multiple therapy areas, discussing hot topics including topic overviews, expert opinions and conference overviews.

Brought to you by the Adis Journals Group, part of Springer Nature. The primary audience for these podcasts are healthcare professionals, and are published and citable through the journals.

Adis Journal Podcasts

Latest episodes

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy in Individuals with Cardiorenal Disease

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy in Individuals with Cardiorenal Disease

30m 6s

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03518-2. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as...

Podcast: Adherence to Injectables

Podcast: Adherence to Injectables

8m 57s

[FULL TITLE OF PODCAST IF ABRIDGED VERSION PROVIDED]

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link: https://link.springer.com/article/10.1007/s13555-026-01678-1. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a...

First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast

First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast

19m 3s

In this podcast, Eric K. Singhi from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Eric S. Nadler from the Baylor University Medical Center, Dallas, TX, USA discuss the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focus on the efficacy and safety of first-line treatments and sequencing strategies.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-025-01192-y. All conflicts of interest can be...

Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the

Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the

19m 56s

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00406-7. All conflicts of interest can be found online. This podcast is intended for medical professionals.
Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence,...